Approval · Notice of Compliance 25291 · 2021
TEVETEN PLUS: Notice of Compliance 25291
Issued February 25, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25291
- Date
- February 25, 2021
- Company
- BGP Pharma ULCEtobicoke, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety updates to the product monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVETEN PLUS | Not yet assigned | — |
Medicinal ingredients
- HYDROCHLOROTHIAZIDE 12.5 MG per TAB
- EPROSARTAN MESYLATE 600 MG per TAB